| [1] |
Partridge AH, Rumble RB, Carey LA, et al. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer:American Society of Clinical Oncology Clinical Practice Guideline [J]. J Clin Oncol,2014,32(29):3307-3329.
|
| [2] |
Cardoso F, Costa A, Norton L, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)[J]. Breast,2014,23(5):489-502.
|
| [3] |
高亚琳, 杨逸雨, 李靖若. 晚期乳腺癌内分泌治疗现状及展望[J/CD]. 中华乳腺病杂志(电子版),2016,10(1):54-56.
|
| [4] |
Bonneterre J, Buzdar A, Jean-Marc AN, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma [J]. Cancer,2001,92(9):2247-2258.
|
| [5] |
Mouridsen H, Gershanovich M, Sun Y, et al. Phase Ⅲstudy of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group [J]. J Clin Oncol,2003,21(11):2101-2109.
|
| [6] |
Paridaens RJ, Dirix LY, Beex LV, et al. Phase Ⅲstudy comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group[J]. J Clin Oncol,2008,26(30):4883-4890.
|
| [7] |
Yamamoto Y, Ishikawa T, Hozumi Y, et al. Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer [J].BMC Cancer,2013,13:239.
|
| [8] |
Ye QL,Zhai ZM. Toremifene and tamoxifen have similar efficacy in the treatment of patients with breast cancer: a meta-analysis of randomized trials [J]. Mol Biol Rep,2014,41(2):751-756.
|
| [9] |
Marttunen MB, Cacciatore B, Hietanen P, et al. Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women [J]. Br J Cancer,2001,84(7):897-902.
|
| [10] |
Robertson JF, Lindemann JP, Llombart-Cussac A, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST'study[J]. Breast Cancer Res Treat,2012,136(2):503-511.
|
| [11] |
Ellis MJ, Llombart-Cussac A, Feltl D, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase ⅡFIRST study [J]. J Clin Oncol,2015,33(32):3781-3787.
|
| [12] |
Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first- line treatment of oestrogen receptor- positive, HER2- negative,advanced breast cancer (PALOMA-1/TRIO-18):a randomized phase 2 study [J]. Lancet Oncol,2015,16(1):25-35.
|
| [13] |
Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer [J]. N Engl J Med, 2016, 375(20):1925-1936.
|
| [14] |
Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase Ⅲtrial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer[J]. J Clin Oncol,2010,28(30):4594-4600.
|
| [15] |
Di Leo A, Jerusalem G, Petruzelka L, et al. Final overall survival:fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial [J]. J Natl Cancer Inst,2014,106(1):djt337.
|
| [16] |
Dobashi Y, Watanabe Y, Miwa C, et al. Mammalian target of rapamycin: a central node of complex signaling cascades [J]. Int J Clin Exp Pathol,2011,4(5):476-495.
|
| [17] |
Wullschleger S, Loewith R, Hall MN, et al. TOR signaling in growth and metabolism [J]. Cell,2006,124(3):471-484.
|
| [18] |
Alers S, Loffler AS,Wesselborg S,et al. Role of AMPK-mTOR-Ulk1/2 in the regulation of autophagy: cross talk, shortcuts, and feedbacks[J]. Mol Cell Biol,2012,32(1):2-11.
|
| [19] |
Ghayad SE, Bieche I, Vendrell JA, et al. mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels [J]. Cancer Sci, 2008,99(10):1992-2003.
|
| [20] |
Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus exemestane in postmenopausal patients with HR (+) breast cancer:BOLERO-2 final progression- free survival analysis [J]. Adv Ther,2013,30(10):870-884.
|
| [21] |
Chia S, Gradishar W, Mauriac L, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor positive, advanced breast cancer: results from EFECT [J]. J Clin Oncol,2008,26(10):1664-1670.
|
| [22] |
Johnston SR,Kilburn LS,Ellis P,et al. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptorpositive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial [J]. Lancet Oncol,2013,14(10):989-998.
|
| [23] |
周爱萍. 依维莫司临床安全性管理专家意见[J]. 中国新药杂志,2014,23(22):2694-2700.
|
| [24] |
Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumors[J]. Nature,2012,490(7418):61-70.
|
| [25] |
Bosch A, Li Z, Bergamaschi A, et al. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer [J]. Sci Transl Med, 2015, 7(283):283ra51.
|
| [26] |
Miller TW, Balko JM, Fox EM, et al. ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer [J]. Cancer Discov,2011,1(4):338-351.
|
| [27] |
No authors listed. PI3K inhibitor improves PFS in BELLE-2 trial [J].Cancer Discov,2016,6(2):115-116.
|
| [28] |
Maura N, Dickler MD. A phase II study of the PI3K inhibitor taselisib(GDC-0032) combined with fulvestrant (F) in patients (pts) with HER2-negative ( HER2 -), hormone receptor-positive ( HR +)advanced breast cancer (BC) [EB/OL]. [2016-06-03]. http:/ /meetinglibrary.asco.org/content/124326? media=vm&poster=1.
|
| [29] |
Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormonereceptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial[J]. Lancet Oncol,2016,17(4):425-439.
|
| [30] |
Bines J, Dienstmann R, Obadia RM, et al. Activity of megestrol acetate in postmenopausal women with advanced breast cancer after nonsteroidal aromatase inhibitor failure: a phase Ⅱtrial [J]. Ann Oncol,2014,25(4):831-836.
|
| [31] |
马焱, 吴世凯, 孟祥颖,等. 孕激素类药物解救治疗芳香化酶抑制剂耐药的转移性乳腺癌的临床研究[J]. 中国肿瘤临床, 2012,39 (8):443-446.
|
| [32] |
陆益, 吴洪斌. 甲地孕酮的不良反应[J]. 药物不良反应杂志,2003,5(1):26-28.
|